Moderna Inc. Q4 FY2026 Earnings Call Summary

MRNA NASDAQ Healthcare 📅 2026-02-13 🔴 Bearish

⚠️ Not financial advice. This summary is AI-generated for informational purposes only. Always do your own research before making investment decisions. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-04-30 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Moderna reported a full-year 2025 net loss of $(2.8B) and revenue of $1.9 billion, a -40% decrease year-over-year, primarily due to lower COVID vaccine sales. Despite significant cost reductions and pipeline advancements, the company faces a setback with the U.S. FDA's refusal-to-file for its seasonal flu vaccine, impacting its near-term growth strategy.

📊 Key Financial Metrics

Revenue $0.7B

EPS (Diluted) $(7.26)

AI Sentiment 🔴 Bearish While cost reductions are positive, the significant revenue decline, persistent net losses, and the critical U.S. FDA refusal-to-file for a key seasonal vaccine candidate create substantial near-term uncertainty and risk for Moderna's growth trajectory.

✅ What Went Well

✅ Substantial Cost Reductions: Moderna lowered its annual operating expenses by approximately $2.2 billion in 2025, significantly surpassing its cost-reduction targets and contributing to an improved net loss of $(2.8B) compared to the prior year.

✅ Advancing Diverse Pipeline: The company achieved full enrollment in its Phase 3 Norovirus vaccine trial and Phase 2 intismeran autogene trial for muscle invasive bladder cancer, with several key data readouts anticipated in 2026 across infectious diseases, oncology, and rare diseases.

✅ Positive Oncology Clinical Data: Five-year Phase 2b data for the intismeran autogene (mRNA-4157) in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death in adjuvant melanoma, highlighting strong potential in its oncology portfolio.

✅ International Commercial Expansion: Moderna secured long-term agreements for respiratory vaccines with Mexico and Taiwan, and received regulatory approvals for mNEXSPIKE in Canada and Australia, expanding its global market presence and contributing to its 2026 growth strategy.

⚠️ Concerns & Risks

⚠️ U.S. FDA Refusal-to-File for Flu Vaccine: The U.S. FDA issued a Refusal-to-File letter for Moderna's seasonal flu vaccine (mRNA-1010), creating uncertainty and potential significant delays for its entry into the crucial U.S. market, a key part of its future revenue strategy.

⚠️ Continued Revenue Decline: Full-year 2025 revenue decreased by -40% year-over-year to $1.9 billion, primarily due to a significant drop in COVID vaccine sales volume, indicating ongoing challenges in its primary revenue stream and market demand shifts.

⚠️ Persistent Operating Losses: Despite substantial cost reductions, the company reported a full-year net loss of $(2.8B) and projects a further decrease in cash and investments to $5.5-$6.0 billion by year-end 2026, reflecting continued cash burn from extensive R&D investments.

⚠️ Challenging U.S. Market Environment: The CEO noted a 'continued challenging environment in the U.S.,' which, combined with the FDA's flu vaccine decision, suggests significant headwinds for domestic market penetration and growth, potentially impacting the 2026 revenue targets.

🔮 CEO / Management Guidance

Moderna's management reiterated its plan to achieve up to 10% revenue growth in 2026 compared to 2025, with an anticipated 50/50 split between U.S. and international markets. They also expect to maintain GAAP operating expense reductions, with Research and Development expenses projected at approximately $3.0 billion and Selling, General and Administrative expenses at $1.0 billion for the year.

💬 Key Quote

In 2025, we sharpened our commercial execution, launched our third product and brought online three international manufacturing sites, while advancing our mRNA pipeline. At the same time, we lowered our annual operating expenses by approximately $2.2 billion, significantly surpassing our cost-reduction targets.” — Stéphane Bancel, Chief Executive Officer

🏢 About Moderna Inc.

Moderna Inc. (MRNA) is a publicly listed company on the NASDAQ exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

MRNA NASDAQ Healthcare All Moderna Inc. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

📁 More from Moderna Inc.

View all earnings summaries for Moderna Inc. →